KUALA LUMPUR, March 23 (Bernama) -- My E.G Services Bhd (MyEG) is offering Malaysia a COVID-19 rapid test kit, pending government approval and which has fulfilled regulatory requirements in the United States, clearing the way for the sale of the set there.

It said the test kit, developed by a reputable Chinese biomedical company, has qualified for emergency use authorisation granted by the US Food and Drug Administration (FDA) under a policy to accelerate detection and diagnosis during public health emergencies.

“The authorisation by the FDA for the test kit is in addition to the European CE mark (meaning it meets Europe's standards), which certifies conformity with health, safety, and environmental protection standards, obtained earlier.

“The rapid test kit in Malaysia is pending approval and certification by the Ministry of Health,” it said in a statement today.

It said the acceptance of the test kit worldwide, including in major regions like the US and Europe, was timely amidst growing acknowledgement worldwide of the need for faster and more widespread detection capacities in the fight to contain the spread of the virus.

The test kit enables early detection of the COVID-19 virus through the use of blood samples obtained from finger-pricking, specifically by detecting the presence of antibodies. 

Test results are generated on-site within minutes, with no requirement for the time-consuming process of sending samples to external diagnostic laboratories.

Due to the simplicity of use of the rapid test kit, MyEG believes it is an accessible and affordable option to increase testing and early detection amongst Malaysians, thus boosting testing capacity in the country and helping reduce the strain on existing public health facilities.

MyEG, an MSC-status company listed on the Main Market of Bursa Malaysia Securities Bhd, is Malaysia’s e-government services provider.